High affinity engineered T-cell receptors targeting cmv infected cells
AssigneeBoard of Regents, The University of Texas System
InventorsJennifer A. Maynard, Ellen Wagner, Ahlam N. Qerqez, Annalee Nguyen
Life of this patent
Estimating the term…
Abstract
Provided herein are engineered T-celi receptors (TCRs) having nanomoiar affinity for the immuno-dominant pp65 peptide residing between residues 495-503 (NLV) in complex with HLA-A2*02:01. The TCRs may be membrane-hound TCRs, soluble TCRs, chimeric TCRs, or chimeric antigen receptors. Also provided are methods of using the engineered TCRs to treat diseases, monitor disease progression, monitor vaccine efficacy, and detecting NLV/A2 presentation on the surface of cells.
Claims20
An engineered T-cell receptor (TCR) comprising an alpha chain comprising the CDR1, CDR2, and CDR3 from one of SEQ ID NOs:
- 19-26 and 74-76 and a beta chain comprising the CDR1, CDR2, and CDR3 from one of SEQ ID NOs:
- 28-38 and 67-68.
Dependencies are inferred from the claim text.